- Investing.com
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Metrics to compare | IPN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIPNPeersSector | |
---|---|---|---|---|
P/E Ratio | 13.5x | 20.5x | −0.7x | |
PEG Ratio | 0.27 | 0.13 | 0.00 | |
Price/Book | 2.2x | 2.9x | 2.6x | |
Price / LTM Sales | 2.6x | 2.3x | 3.2x | |
Upside (Analyst Target) | 9.7% | 20.8% | 44.5% | |
Fair Value Upside | Unlock | 14.7% | 6.6% | Unlock |